Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
7 High-Yield Blue-Chips You'll Want To Own In The Coming Recession
01:11pm, Wednesday, 30'th Mar 2022 Seeking Alpha
Recessions and bear markets are a healthy and normal part of the economic and market cycle. See 7 blue-chip stocks you'll want to own in a recession.
7 High-Yield Blue-Chips You'll Want To Own In The Coming Recession
09:11am, Wednesday, 30'th Mar 2022
Recessions and bear markets are a healthy and normal part of the economic and market cycle, just like corrections and pullbacks.
The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences
10:56am, Tuesday, 29'th Mar 2022 Zacks Investment Research
Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.
Top Stock Reports for Visa, Novartis & Deere
06:06pm, Monday, 28'th Mar 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Novartis AG (NVS), and Deere & Company (DE).
Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah
05:27pm, Monday, 28'th Mar 2022 Zacks Investment Research
Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.
Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah
03:03pm, Monday, 28'th Mar 2022
Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
12:00pm, Sunday, 27'th Mar 2022 The Motley Fool
Another player has stuffed its pipeline with many coronavirus candidates.
The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer
10:35am, Friday, 25'th Mar 2022 Zacks Investment Research
Novartis, Merck and Pfizer have been included in this Analyst Blog.
Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer
05:39pm, Thursday, 24'th Mar 2022 Zacks Investment Research
The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.
Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer
03:03pm, Thursday, 24'th Mar 2022
The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
03:00pm, Thursday, 24'th Mar 2022 The Motley Fool
These two companies offer products that are always in demand, regardless of economic conditions.
Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds
02:14pm, Thursday, 24'th Mar 2022 Zacks Investment Research
FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto
Novartis AG (NYSE: NVS) said the U.S.
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
12:31pm, Tuesday, 22'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer
Merck & Co., Inc. (NYSE: MRK) s
